SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.

Yusuke Minami, Shinji Kohsaka, Masumi Tsuda, Kazuhiro Yachi, Nobuaki Hatori, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, Akio Minami, Norimasa Iwasaki, Shinya Tanaka

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

MicroRNA (miRNA) can function as tumor suppressors or oncogenes, and also as potential specific cancer biomarkers; however, there are few published studies on miRNA in synovial sarcomas, and their function remains unclear. We transfected the OncomiR miRNA Precursor Virus Library into synovial sarcoma Fuji cells followed by a colony formation assay to identify miRNAs to confer an aggressive tumorigenicity, and identified miR-17-5p from the large colonies. MiR-17 was found to be induced by a chimeric oncoprotein SS18-SSX specific for synovial sarcoma, and all examined cases of human synovial sarcoma expressed miR-17, even at high levels in several cases. Overexpression of miR-17 in synovial sarcoma cells, Fuji and HS-SYII, increased colony forming ability in addition to cell growth, but not cell motility and invasion. Tumor volume formed in mice in vivo was significantly increased by miR-17 overexpression with a marked increase of MIB-1 index. According to PicTar and Miranda algorithms, which predicted CDKN1A (p21) as a putative target of miR-17, a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA. Indeed, p21 protein level was remarkably decreased by miR-17 overexpression in a p53-independent manner. It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance. Meanwhile, introduction of anti-miR-17 in Fuji and HS-SYII cells significantly decreased cell growth, consistent with rescued expression of p21. Taken together, miR-17 promotes the tumor growth of synovial sarcomas by post-transcriptional suppression of p21, which may be amenable to innovative therapeutic targeting in synovial sarcoma.

Original languageEnglish
Pages (from-to)1152-1159
Number of pages8
JournalCancer science
Volume105
Issue number9
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Synovial Sarcoma
MicroRNAs
Growth
Neoplasms
Oncogene Proteins
3' Untranslated Regions
Tumor Biomarkers
Tumor Burden
Luciferases
Oncogenes
Drug Resistance
Doxorubicin
Cell Movement
Viruses
Messenger RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Minami, Y., Kohsaka, S., Tsuda, M., Yachi, K., Hatori, N., Tanino, M., ... Tanaka, S. (2014). SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer science, 105(9), 1152-1159. https://doi.org/10.1111/cas.12479

SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. / Minami, Yusuke; Kohsaka, Shinji; Tsuda, Masumi; Yachi, Kazuhiro; Hatori, Nobuaki; Tanino, Mishie; Kimura, Taichi; Nishihara, Hiroshi; Minami, Akio; Iwasaki, Norimasa; Tanaka, Shinya.

In: Cancer science, Vol. 105, No. 9, 01.01.2014, p. 1152-1159.

Research output: Contribution to journalArticle

Minami, Y, Kohsaka, S, Tsuda, M, Yachi, K, Hatori, N, Tanino, M, Kimura, T, Nishihara, H, Minami, A, Iwasaki, N & Tanaka, S 2014, 'SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.', Cancer science, vol. 105, no. 9, pp. 1152-1159. https://doi.org/10.1111/cas.12479
Minami Y, Kohsaka S, Tsuda M, Yachi K, Hatori N, Tanino M et al. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer science. 2014 Jan 1;105(9):1152-1159. https://doi.org/10.1111/cas.12479
Minami, Yusuke ; Kohsaka, Shinji ; Tsuda, Masumi ; Yachi, Kazuhiro ; Hatori, Nobuaki ; Tanino, Mishie ; Kimura, Taichi ; Nishihara, Hiroshi ; Minami, Akio ; Iwasaki, Norimasa ; Tanaka, Shinya. / SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1. In: Cancer science. 2014 ; Vol. 105, No. 9. pp. 1152-1159.
@article{e5993705665c4e1e8818d2d1c7764576,
title = "SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.",
abstract = "MicroRNA (miRNA) can function as tumor suppressors or oncogenes, and also as potential specific cancer biomarkers; however, there are few published studies on miRNA in synovial sarcomas, and their function remains unclear. We transfected the OncomiR miRNA Precursor Virus Library into synovial sarcoma Fuji cells followed by a colony formation assay to identify miRNAs to confer an aggressive tumorigenicity, and identified miR-17-5p from the large colonies. MiR-17 was found to be induced by a chimeric oncoprotein SS18-SSX specific for synovial sarcoma, and all examined cases of human synovial sarcoma expressed miR-17, even at high levels in several cases. Overexpression of miR-17 in synovial sarcoma cells, Fuji and HS-SYII, increased colony forming ability in addition to cell growth, but not cell motility and invasion. Tumor volume formed in mice in vivo was significantly increased by miR-17 overexpression with a marked increase of MIB-1 index. According to PicTar and Miranda algorithms, which predicted CDKN1A (p21) as a putative target of miR-17, a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA. Indeed, p21 protein level was remarkably decreased by miR-17 overexpression in a p53-independent manner. It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance. Meanwhile, introduction of anti-miR-17 in Fuji and HS-SYII cells significantly decreased cell growth, consistent with rescued expression of p21. Taken together, miR-17 promotes the tumor growth of synovial sarcomas by post-transcriptional suppression of p21, which may be amenable to innovative therapeutic targeting in synovial sarcoma.",
author = "Yusuke Minami and Shinji Kohsaka and Masumi Tsuda and Kazuhiro Yachi and Nobuaki Hatori and Mishie Tanino and Taichi Kimura and Hiroshi Nishihara and Akio Minami and Norimasa Iwasaki and Shinya Tanaka",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/cas.12479",
language = "English",
volume = "105",
pages = "1152--1159",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.

AU - Minami, Yusuke

AU - Kohsaka, Shinji

AU - Tsuda, Masumi

AU - Yachi, Kazuhiro

AU - Hatori, Nobuaki

AU - Tanino, Mishie

AU - Kimura, Taichi

AU - Nishihara, Hiroshi

AU - Minami, Akio

AU - Iwasaki, Norimasa

AU - Tanaka, Shinya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - MicroRNA (miRNA) can function as tumor suppressors or oncogenes, and also as potential specific cancer biomarkers; however, there are few published studies on miRNA in synovial sarcomas, and their function remains unclear. We transfected the OncomiR miRNA Precursor Virus Library into synovial sarcoma Fuji cells followed by a colony formation assay to identify miRNAs to confer an aggressive tumorigenicity, and identified miR-17-5p from the large colonies. MiR-17 was found to be induced by a chimeric oncoprotein SS18-SSX specific for synovial sarcoma, and all examined cases of human synovial sarcoma expressed miR-17, even at high levels in several cases. Overexpression of miR-17 in synovial sarcoma cells, Fuji and HS-SYII, increased colony forming ability in addition to cell growth, but not cell motility and invasion. Tumor volume formed in mice in vivo was significantly increased by miR-17 overexpression with a marked increase of MIB-1 index. According to PicTar and Miranda algorithms, which predicted CDKN1A (p21) as a putative target of miR-17, a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA. Indeed, p21 protein level was remarkably decreased by miR-17 overexpression in a p53-independent manner. It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance. Meanwhile, introduction of anti-miR-17 in Fuji and HS-SYII cells significantly decreased cell growth, consistent with rescued expression of p21. Taken together, miR-17 promotes the tumor growth of synovial sarcomas by post-transcriptional suppression of p21, which may be amenable to innovative therapeutic targeting in synovial sarcoma.

AB - MicroRNA (miRNA) can function as tumor suppressors or oncogenes, and also as potential specific cancer biomarkers; however, there are few published studies on miRNA in synovial sarcomas, and their function remains unclear. We transfected the OncomiR miRNA Precursor Virus Library into synovial sarcoma Fuji cells followed by a colony formation assay to identify miRNAs to confer an aggressive tumorigenicity, and identified miR-17-5p from the large colonies. MiR-17 was found to be induced by a chimeric oncoprotein SS18-SSX specific for synovial sarcoma, and all examined cases of human synovial sarcoma expressed miR-17, even at high levels in several cases. Overexpression of miR-17 in synovial sarcoma cells, Fuji and HS-SYII, increased colony forming ability in addition to cell growth, but not cell motility and invasion. Tumor volume formed in mice in vivo was significantly increased by miR-17 overexpression with a marked increase of MIB-1 index. According to PicTar and Miranda algorithms, which predicted CDKN1A (p21) as a putative target of miR-17, a luciferase assay was performed and revealed that miR-17 directly targets the 3'-UTR of p21 mRNA. Indeed, p21 protein level was remarkably decreased by miR-17 overexpression in a p53-independent manner. It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance. Meanwhile, introduction of anti-miR-17 in Fuji and HS-SYII cells significantly decreased cell growth, consistent with rescued expression of p21. Taken together, miR-17 promotes the tumor growth of synovial sarcomas by post-transcriptional suppression of p21, which may be amenable to innovative therapeutic targeting in synovial sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=85027929100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027929100&partnerID=8YFLogxK

U2 - 10.1111/cas.12479

DO - 10.1111/cas.12479

M3 - Article

VL - 105

SP - 1152

EP - 1159

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 9

ER -